申请人:Board of Regents, The University of Texas System
公开号:US20190016713A1
公开(公告)日:2019-01-17
The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
[EN] BICYCLIC COMPOUND AS HPK1 INHIBITOR AND APPLICATION THEREOF<br/>[FR] COMPOSÉ BICYCLIQUE SERVANT D'INHIBITEUR DE HPK1 ET SON UTILISATION<br/>[ZH] 作为HPK1抑制剂的双环类化合物及其应用
Jorritsma, R.; Steinberg, H.; Boer, Th. J. de, Recueil des Travaux Chimiques des Pays-Bas, 1981, vol. 100, # 5, p. 184 - 194
作者:Jorritsma, R.、Steinberg, H.、Boer, Th. J. de
DOI:——
日期:——
JORRITSMA R.; STEINBERG H.; BOER T. J. DE, REC. TRAV. CHIM. PAYS-BAS, 1981, 100, NO 5, 184-194
作者:JORRITSMA R.、 STEINBERG H.、 BOER T. J. DE
DOI:——
日期:——
[EN] PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS<br/>[FR] DÉRIVÉS DE PYRIDINAMINE ET LEUR UTILISATION EN TANT QUE MODULATEURS DES CANAUX POTASSIQUES
申请人:[en]XENON PHARMACEUTICALS INC.
公开号:WO2023239729A1
公开(公告)日:2023-12-14
The present disclosure is directed to compounds of Formula (I): wherein m, n, Y, R1, R2, R3, R4and R5are each as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of Formula (I), as described herein, which are useful as voltage-gated potassium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.